BACKGROUND: This analysis evaluated the effects of the serotonin-norepinephrine reuptake inhibitor, desvenlafaxine (administered as desvenlafaxine succinate), on anxiety symptoms associated with depression. METHODS: Data were pooled from 9 randomized, placebo-controlled, double-blind, 8 week studies of desvenlafaxine (50-400 mg/day, fixed or flexible dose) in patients with major depressive disorder (MDD), without a primary anxiety diagnosis. Changes from baseline in scores on the anxiety/somatization factor of the 17-item Hamilton Rating Scale for Depression (HAM-D17) and on the Covi Anxiety Scale at the final evaluation (last observation carried forward) were compared between desvenlafaxine and placebo groups using analysis of covariance. RESULTS: In the overall data set (intent to treat n=2,913 [desvenlafaxine, n=1,805; placebo, n=1,108]), desvenlafaxine was associated with significantly greater reductions compared with placebo in scores on the HAM-D17 anxiety/somatization factor (-3.41 vs -2.92, P<.001) and Covi Anxiety Scale (-1.35 vs -1.04, P<.001). In the subset of fixed-dose studies, significant differences were observed for all dose groups on the HAM-D17 anxiety/somatization factor (P= or <.011), and for the 50, 100, and 200 mg/day dose groups on the Covi Anxiety Scale (all P= or <.015 vs placebo). CONCLUSIONS:Desvenlafaxine was associated with significantly greater improvement in anxiety symptoms compared with placebo in patients with MDD.
RCT Entities:
BACKGROUND: This analysis evaluated the effects of the serotonin-norepinephrine reuptake inhibitor, desvenlafaxine (administered as desvenlafaxine succinate), on anxiety symptoms associated with depression. METHODS: Data were pooled from 9 randomized, placebo-controlled, double-blind, 8 week studies of desvenlafaxine (50-400 mg/day, fixed or flexible dose) in patients with major depressive disorder (MDD), without a primary anxiety diagnosis. Changes from baseline in scores on the anxiety/somatization factor of the 17-item Hamilton Rating Scale for Depression (HAM-D17) and on the Covi Anxiety Scale at the final evaluation (last observation carried forward) were compared between desvenlafaxine and placebo groups using analysis of covariance. RESULTS: In the overall data set (intent to treat n=2,913 [desvenlafaxine, n=1,805; placebo, n=1,108]), desvenlafaxine was associated with significantly greater reductions compared with placebo in scores on the HAM-D17 anxiety/somatization factor (-3.41 vs -2.92, P<.001) and Covi Anxiety Scale (-1.35 vs -1.04, P<.001). In the subset of fixed-dose studies, significant differences were observed for all dose groups on the HAM-D17 anxiety/somatization factor (P= or <.011), and for the 50, 100, and 200 mg/day dose groups on the Covi Anxiety Scale (all P= or <.015 vs placebo). CONCLUSIONS:Desvenlafaxine was associated with significantly greater improvement in anxiety symptoms compared with placebo in patients with MDD.
Authors: Jessica Bomyea; Ariel Lang; Michelle G Craske; Denise A Chavira; Cathy D Sherbourne; Raphael D Rose; Daniela Golinelli; Laura Campbell-Sills; Stacy S Welch; Greer Sullivan; Alexander Bystritsky; Peter Roy-Byrne; Murray B Stein Journal: Psychiatry Res Date: 2015-07-21 Impact factor: 3.222
Authors: Caren Nádia Soares de Sousa; Ingridy da Silva Medeiros; Germana Silva Vasconcelos; Gabriel Ângelo de Aquino; Francisco Maurício Sales Cysne Filho; Jamily Cunha de Almeida; Ana Paula Negreiros Nunes Alves; Danielle S Macêdo; Luzia Kalyne Almeida Moreira Leal; Silvânia Maria Mendes Vasconcelos Journal: Oxid Med Cell Longev Date: 2022-08-19 Impact factor: 7.310
Authors: Erick H Turner; Andrea Cipriani; Toshi A Furukawa; Georgia Salanti; Ymkje Anna de Vries Journal: PLoS Med Date: 2022-01-19 Impact factor: 11.069